Alessa Therapeutics, a San Carlos, CA-based clinical-stage drug growth firm, raised $15M in Seed funding.
The spherical was led by Mission BioCapital, with participation from Johnson & Johnson.
The corporate intends to make use of the funds to advance growth of its lead program, Enolen®, a novel enzalutamide-eluting seed implant for the therapy of localized prostate most cancers.
Led by CEO and Founder Pamela Munster, Alessa Therapeutics is targeted on creating selective and sustained localized drug supply for early interception of most cancers. Its proprietary localized drug-delivering implants are designed for sustained launch of an anti-androgen selectively to the prostate thus limiting systemic uncomfortable side effects regardless of offering therapeutic concentrations within the prostate.
FinSMEs
13/12/2024
